CD70 and nonpapillary renal cell carcinoma: A next-generation product, CTX131, exhibited enhanced expansion and antitumour activity in preclinical models, further supporting the therapeutic potential of CD70-targeted CAR-T cells in ccRCC and other CD70-positive solid tumours [154].